[go: up one dir, main page]

MEP2808A - Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju - Google Patents

Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju

Info

Publication number
MEP2808A
MEP2808A MEP-28/08A MEP2808A MEP2808A ME P2808 A MEP2808 A ME P2808A ME P2808 A MEP2808 A ME P2808A ME P2808 A MEP2808 A ME P2808A
Authority
ME
Montenegro
Prior art keywords
methods
sclerostin
tgf
mineral density
antibodies specific
Prior art date
Application number
MEP-28/08A
Other languages
Bosnian (bs)
English (en)
Inventor
David G Winkler
Jiye Shi
John Latham
Original Assignee
Celltech R & D Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R & D Inc filed Critical Celltech R & D Inc
Publication of MEP2808A publication Critical patent/MEP2808A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
MEP-28/08A 2003-06-16 2004-06-15 Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju MEP2808A (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47897703P 2003-06-16 2003-06-16
PCT/US2004/018912 WO2005014650A2 (en) 2003-06-16 2004-06-15 Antibodies specific for sclerostin and methods for increasing bone mineralization

Publications (1)

Publication Number Publication Date
MEP2808A true MEP2808A (xx) 2010-02-10

Family

ID=34135049

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-28/08A MEP2808A (xx) 2003-06-16 2004-06-15 Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju

Country Status (17)

Country Link
US (12) US7381409B2 (xx)
EP (1) EP1636270B1 (xx)
JP (2) JP4688802B2 (xx)
KR (1) KR101210187B1 (xx)
CN (1) CN1835974A (xx)
AU (1) AU2004262640B2 (xx)
BR (1) BRPI0411552A (xx)
CA (1) CA2529623A1 (xx)
EA (1) EA015166B1 (xx)
ES (1) ES2586401T3 (xx)
IL (1) IL172598A0 (xx)
ME (1) MEP2808A (xx)
NO (1) NO345763B1 (xx)
NZ (1) NZ544618A (xx)
RS (1) RS20050934A (xx)
WO (1) WO2005014650A2 (xx)
ZA (1) ZA200600388B (xx)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CA2352532C (en) 1998-11-27 2014-10-14 Darwin Discovery Ltd. Compositions and methods for increasing bone mineralization
AU2003221841A1 (en) 2002-04-03 2003-10-27 Celltech R And D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
CA2574777C (en) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
AU2012238247B2 (en) * 2005-05-03 2016-06-16 Amgen, Inc. Sclerostin binding agents
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP1973559B1 (en) 2005-11-23 2013-01-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth
WO2008133722A2 (en) * 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
EP2097450A2 (en) * 2006-11-10 2009-09-09 Amgen Inc. Antibody-based diagnostics and therapeutics
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2009131553A2 (en) 2006-12-29 2009-10-29 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
RU2473362C2 (ru) 2007-02-01 2013-01-27 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
KR20180083967A (ko) 2007-02-09 2018-07-23 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
EA018204B1 (ru) * 2007-03-20 2013-06-28 Эли Лилли Энд Компани Антитела против склеростина
DK2152880T3 (da) 2007-06-01 2011-11-28 Omt Inc Sammensætninger og fremgangsmåder til hæmning af endogene immunoglobulingener og produktion af transgene, humane idiotype antistoffer
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
JP2011506483A (ja) * 2007-12-14 2011-03-03 アムジエン・インコーポレーテツド 抗スクレロスチン抗体を用いた骨折の治療方法
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
ES2949049T3 (es) 2008-08-14 2023-09-25 Acceleron Pharma Inc Trampas de GDF
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
US8338377B2 (en) 2009-03-30 2012-12-25 Acceleron Pharma Inc. BMP-ALK3 antagonists and uses for promoting bone growth
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) * 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
KR20210034684A (ko) 2009-06-12 2021-03-30 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
AU2010322011B2 (en) 2009-11-17 2016-03-31 Acceleron Pharma Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
MX2012011629A (es) 2010-04-07 2013-03-05 Abbvie Inc Proteinas de union a tnf-alfa.
US20130138221A1 (en) 2010-04-16 2013-05-30 Novartis Ag Methods and compositions for improving implant osseointegration
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
EP2576786B1 (en) * 2010-05-27 2016-04-06 The University of Hong Kong High-affinity nucleic acid aptamers against sclerostin protein
US9493541B2 (en) * 2010-06-07 2016-11-15 Joshua Rabbani Antibodies specific for sulfated sclerostin
US9617323B2 (en) 2010-06-07 2017-04-11 Joshua Rabbani Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
US20140308242A1 (en) 2010-10-21 2014-10-16 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
PT3111954T (pt) 2010-11-05 2019-07-10 Novartis Ag Métodos de tratamento da espondilite anquilosante usando anticorpos anti-il-17
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
CN103649118A (zh) 2011-03-01 2014-03-19 安进公司 双特异性结合剂
SG193610A1 (en) 2011-03-25 2013-11-29 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
US20140127192A1 (en) 2011-04-19 2014-05-08 Amgen Inc Method for treating osteoporosis
EP2702408A1 (en) 2011-04-29 2014-03-05 Novartis AG Methods of treating squamous cell carcinoma related applications
ES2667554T3 (es) 2011-08-04 2018-05-11 Amgen Inc. Método para el tratamiento de los defectos de espacio óseo
BR112014009799A2 (pt) 2011-10-24 2017-06-13 Abbvie Inc imunoligantes dirigidos conra tnf
WO2013063110A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Bispecific immunobinders directed against tnf and il-17
SG11201401791WA (en) * 2011-10-24 2014-08-28 Abbvie Inc Immunobinders directed against sclerostin
MX354270B (es) 2011-12-28 2018-02-21 Amgen Inc Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. .
EP2869844B2 (en) 2012-07-05 2023-06-21 UCB Pharma S.A. Treatment for bone diseases
WO2014015217A1 (en) 2012-07-19 2014-01-23 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
CN110639024A (zh) 2013-05-03 2020-01-03 西莱克塔生物科技公司 用于增强cd4+调节性t细胞的方法和组合物
CN103550785B (zh) * 2013-10-30 2016-05-18 清华大学深圳研究生院 TGF-β受体结合蛋白-1的用途
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
BR112016029226A2 (pt) 2014-06-13 2017-10-17 Acceleron Pharma Inc métodos e composições para o tratamento de úlceras
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
TWI773117B (zh) 2014-12-03 2022-08-01 美商西建公司 活化素-actrii拮抗劑及治療貧血之用途
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
KR102584953B1 (ko) * 2015-03-13 2023-10-04 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항 스클레로스틴 항체, 이의 항원 결합 단편 및 의학적 용도
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
GB201609235D0 (en) 2016-05-25 2016-07-06 Univ Cape Town Production of a horseradish peroxidase-IGG fusion protein
GB201610044D0 (en) * 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
KR20190037261A (ko) 2016-08-08 2019-04-05 암젠 인크 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
CN110325548B (zh) 2016-12-21 2023-11-17 美莱奥生物制药第三有限公司 抗硬化蛋白抗体在治疗成骨不全症中的用途
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
CN110662421B (zh) 2017-01-19 2023-03-24 欧莫诺艾比公司 来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体
MX2019010757A (es) 2017-03-11 2020-01-20 Selecta Biosciences Inc Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
RU2647571C1 (ru) * 2017-08-25 2018-03-16 Владимир Глебович Лунин Рекомбинантный белок склеростина, способ получения рекомбинантного белка склеростина, способ повышения костной массы позвоночного животного
CN108101984B (zh) * 2017-12-18 2019-10-15 中国人民解放军总医院 骨硬化蛋白单链抗体的制备方法和用途
CN111712573B (zh) 2018-02-12 2023-10-20 安沛治疗有限公司 针对骨硬化蛋白的适体及其用途
JP7405764B2 (ja) 2018-03-30 2023-12-26 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
EP3833327A1 (en) 2018-08-10 2021-06-16 Amgen Inc. Method of preparing an antibody pharmaceutical formulation
CN114630677A (zh) 2019-08-12 2022-06-14 安进公司 抗硬骨素抗体配制品
CN113214479B (zh) * 2021-05-08 2022-03-18 四川大学 一种矿化防龋材料及其制备方法
TW202510908A (zh) 2023-07-19 2025-03-16 美商安進公司 用於治療性蛋白質配製物的緩衝液製備方法

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US5272254A (en) 1984-10-02 1993-12-21 Biogen Inc. Production of streptavidin-like polypeptides
DE3583940D1 (de) 1984-10-02 1991-10-02 Harry M Meade Herstellung von streptavidinaehnlichen polypeptiden.
SG64329A1 (en) 1984-11-16 1999-04-27 American Cyanamid Co Antitumor antibiotics (LL-E33288 complex)
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB8723661D0 (en) 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
DE3851682T2 (de) 1987-10-30 1995-05-04 American Cyanamid Co Targetformer von Antitumor-Methyltrithioagenzien.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
DE69024953T3 (de) 1989-05-04 2005-01-27 Southern Research Institute, Birmingham Einkapselungsverfahren
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
EP0554376A4 (en) 1990-10-22 1994-08-24 Fox Chase Cancer Center Dna construct for providing rna therapy
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
AU668349B2 (en) * 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
DE4135543A1 (de) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh Rekombinantes core-streptavidin
EP0578515A3 (en) 1992-05-26 1995-05-10 Bristol Myers Squibb Co Humanized monoclonal antibodies.
WO1993024631A1 (en) 1992-05-29 1993-12-09 E.I. Du Pont De Nemours And Company PRODUCTION OF STREPTAVIDIN FROM $i(BACILLUS SUBTILIS)
DK0678034T3 (da) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
NZ267838A (en) 1993-06-07 1997-12-19 Genentech Inc Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) * 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
JPH10511840A (ja) 1994-04-29 1998-11-17 クリエイティブ バイオモレキュールズ，インコーポレイテッド 形態形成タンパク質特異細胞表面レセプターおよびその使用
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
EP0871705A4 (en) * 1995-06-05 2000-01-26 Human Genome Sciences Inc CCN TYPE HUMAN GROWTH FACTOR
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6207153B1 (en) 1996-05-22 2001-03-27 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
WO2000075317A2 (en) * 1999-06-09 2000-12-14 Genentech, Inc. Compositions and methods for the treatment of tumor
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
DE69839147T2 (de) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
WO1999006554A2 (en) 1997-08-01 1999-02-11 Genset 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
KR100581991B1 (ko) 1998-02-12 2006-05-23 이뮨 컴플렉스, 코포레이션 변형된 ｂ형 간염 코어 단백질 및 이의 유도체
GB9818881D0 (en) * 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
US6544485B1 (en) 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
CA2352532C (en) 1998-11-27 2014-10-14 Darwin Discovery Ltd. Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU2753100A (en) 1999-02-03 2000-08-25 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
JP4141095B2 (ja) 1999-10-29 2008-08-27 三洋電機株式会社 半導体装置とその製造方法
JP2003525611A (ja) 2000-03-02 2003-09-02 アムジェン インコーポレーテッド コルディン様−２分子およびその使用
CA2410912A1 (en) * 2000-06-01 2001-12-06 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
JP2004520005A (ja) 2000-06-19 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー オステオレビン遺伝子多型性
CA2421056A1 (en) 2000-09-01 2002-03-28 Genentech, Inc. A polypeptide for use as a diagnostic marker for the presence of colon tumours
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
DE10145772A1 (de) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA·1·-Pyrroline
JP4467304B2 (ja) 2001-12-06 2010-05-26 バイオコントロール システムズ，インコーポレイティド サンプル収集および試験システム
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
JP4662714B2 (ja) 2002-03-01 2011-03-30 セルテック アール アンド ディー インコーポレイテッド 骨密度を増減させる方法
AU2003221841A1 (en) 2002-04-03 2003-10-27 Celltech R And D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
WO2003106657A2 (en) * 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
EP1572122A4 (en) 2002-11-01 2008-04-09 Us Gov Health & Human Serv METHOD FOR PREVENTING INFECTIONS OF BIOTERRORISM AGENTS WITH IMMUNOSTIMULATING CPG OLIGONUCLEOTIDES
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) * 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
JP4660471B2 (ja) 2003-03-14 2011-03-30 セルテック アール アンド ディー， インコーポレイテッド ＴＧＦβ結合タンパク質のリガンドおよびその使用
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
NZ544618A (en) * 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP2097450A2 (en) * 2006-11-10 2009-09-09 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2008133722A2 (en) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
WO2009131553A2 (en) 2006-12-29 2009-10-29 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
CA2675639A1 (en) 2007-02-02 2008-08-07 Novartis Ag Modulators of sclerostatin biniding partners for treating bone-related disorders
EA018204B1 (ru) 2007-03-20 2013-06-28 Эли Лилли Энд Компани Антитела против склеростина
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
BRPI0820327A2 (pt) 2007-11-02 2020-10-06 Novartis Ag moléculas e métodos para modulação de proteína relacionada ao receptor de lipoproteína de baixa densidade 6 (lrp6)
JP2011506483A (ja) * 2007-12-14 2011-03-03 アムジエン・インコーポレーテツド 抗スクレロスチン抗体を用いた骨折の治療方法

Also Published As

Publication number Publication date
US20110206677A1 (en) 2011-08-25
AU2004262640B2 (en) 2010-12-23
US20130064829A1 (en) 2013-03-14
JP2011105729A (ja) 2011-06-02
US20130064830A1 (en) 2013-03-14
KR20060035622A (ko) 2006-04-26
US20110206678A1 (en) 2011-08-25
ZA200600388B (en) 2008-06-25
US20050106683A1 (en) 2005-05-19
WO2005014650A2 (en) 2005-02-17
WO2005014650A3 (en) 2005-07-28
ES2586401T3 (es) 2016-10-14
US9657095B2 (en) 2017-05-23
JP4688802B2 (ja) 2011-05-25
NO20060236L (no) 2006-03-14
US7381409B2 (en) 2008-06-03
NZ544618A (en) 2009-02-28
US8563271B2 (en) 2013-10-22
US20180072801A1 (en) 2018-03-15
US8992911B2 (en) 2015-03-31
US20090117118A1 (en) 2009-05-07
CN1835974A (zh) 2006-09-20
US20200231664A1 (en) 2020-07-23
US7868134B2 (en) 2011-01-11
EA200600038A1 (ru) 2006-06-30
US20240209075A1 (en) 2024-06-27
US20150191537A1 (en) 2015-07-09
EP1636270B1 (en) 2016-07-20
JP2007537130A (ja) 2007-12-20
US20120321636A1 (en) 2012-12-20
US20110195453A1 (en) 2011-08-11
RS20050934A (sr) 2008-04-04
EP1636270A2 (en) 2006-03-22
US9011856B2 (en) 2015-04-21
AU2004262640A1 (en) 2005-02-17
US11702468B2 (en) 2023-07-18
BRPI0411552A (pt) 2006-08-01
NO345763B1 (no) 2021-07-19
KR101210187B1 (ko) 2012-12-07
CA2529623A1 (en) 2005-02-17
IL172598A0 (en) 2006-04-10
EA015166B1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
MEP2808A (xx) Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju
MEP3108A (xx) Kompozicije i postupci za povećanje mineralizacije kostiju
PH12015501848A1 (en) Binding agents
MY174493A (en) Binding agents
WO2006118772A3 (en) Fcrn antibodies and uses thereof
PL1608399T3 (pl) Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
WO2007098198A3 (en) Modulation of bone formation
WO2006117782A3 (en) Recombinant antibodies against cd55 and cd59 and uses thereof
TW200745159A (en) IL-6 binding proteins
TW200643031A (en) Pest control
WO2004070347A3 (en) Screening for modulators of fat storage
HK1151803B (en) Sclerostin binding agents
WO2006000753A3 (en) Use of flj40787, a protein involved in colon, colorectal, ovarian, lung and/or liver cancer
WO2006008266A3 (en) Factor xi-binding proteins
WO2006123122A3 (en) Psk- i and its modulators for the treatment/diagnosis of cancer
WO2007021733A3 (en) Methods and compositions for enhancing protein folding